NVG-291 in Spinal Cord Injury Subjects
Abroad (travel likely)TerminatedPHASE1, PHASE2
Conditions
Spinal Cord Injuries · Chronic Spinal Cord Injury · Subacute Spinal Cord Injury
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Shirley Ryan AbilityLab, Chicago, Illinois, United States
Study leads
Randall Kaye, M.D.
Study Director
NervGen Pharma